Next Article in Journal
Sublingual Atropine Administration as a Tool to Decrease Salivary Glands’ PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [68Ga]Ga-PSMA-11
Next Article in Special Issue
Therapeutic Response Monitoring with 89Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
Previous Article in Journal
PLGA Carriers for Controlled Release of Levofloxacin in Anti-Tuberculosis Therapy
Previous Article in Special Issue
Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071
 
 
Article

Article Versions Notes

Pharmaceutics 2022, 14(6), 1274; https://doi.org/10.3390/pharmaceutics14061274
Action Date Notes Link
article pdf uploaded. 15 June 2022 16:21 CEST Version of Record https://www.mdpi.com/1999-4923/14/6/1274/pdf-vor
article supplementary file uploaded. 15 June 2022 16:21 CEST - https://www.mdpi.com/1999-4923/14/6/1274#supplementary
article xml file uploaded 16 June 2022 08:40 CEST Original file -
article xml uploaded. 16 June 2022 08:40 CEST Update https://www.mdpi.com/1999-4923/14/6/1274/xml
article pdf uploaded. 16 June 2022 08:40 CEST Updated version of record https://www.mdpi.com/1999-4923/14/6/1274/pdf
article html file updated 16 June 2022 08:41 CEST Original file -
article html file updated 17 June 2022 10:07 CEST Update -
article html file updated 12 August 2022 20:37 CEST Update https://www.mdpi.com/1999-4923/14/6/1274/html
Back to TopTop